HitGen Inc. (SHA:688222)

China flag China · Delayed Price · Currency is CNY
24.89
+1.64 (7.05%)
At close: Mar 27, 2026
Market Cap9.94B +46.7%
Revenue (ttm)525.57M +23.1%
Net Income114.02M +122.0%
EPS0.28 +115.4%
Shares Out399.44M
PE Ratio88.89
Forward PE90.51
Dividend0.06 (0.24%)
Ex-Dividend Daten/a
Volume17,863,240
Average Volume10,087,168
Open23.13
Previous Close23.25
Day's Range23.06 - 25.06
52-Week Range11.85 - 42.98
Beta0.48
RSI42.74
Earnings DateApr 29, 2026

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 492
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688222
Full Company Profile

Financial Performance

In 2025, HitGen's revenue was 525.57 million, an increase of 23.09% compared to the previous year's 426.99 million. Earnings were 114.02 million, an increase of 122.01%.

Financial Statements